Strongbridge Biopharma plc (SBBP) is Initiated by H.C. Wainwright to Buy, Price Target at $15

Strongbridge Biopharma plc (SBBP) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $15. H.C. Wainwright advised their investors in a research report released on Apr 25, 2016.

Strongbridge Biopharma plc is a biopharmaceutical company focused on the development in-licensing acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. The Company’s primary focus has been to build its franchise around rare endocrine disorders which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly two rare diseases with a high unmet need for treatment options. The Company intends to use a small focused sales force to market its products if approved in the United States European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.

Strongbridge Biopharma plc

Leave a Reply

Strongbridge Biopharma plc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Strongbridge Biopharma plc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.